ISB, BHRI Collaborate to Better Understand Significant Brain Impairment
ISB has entered into a scientific partnership with the Brain Health & Research Institute (BHRI), which opens its doors on September 3 in Seattle.
BHRI was created by brain health expert Dr. Mary Kay Ross, and is dedicated to the evaluation, prevention, and treatment of neurodegenerative diseases, including Alzheimer’s Disease and dementia.
“Nearly 6 million Americans are suffering currently from Alzheimer’s Disease, and with a new diagnosis every 66 seconds, that number is expected to grow to as many as 16 million in the U.S. alone by 2050. Yet, every effort to develop effective drug therapies has come up empty,” said Ross. “This is why we have joined forces with ISB to provide knowledge, hope, and importantly, results for patients facing the devastating effects of this and other neurodegenerative diseases.”
The ISB-BHRI partnership will create a research database that will further the goals of each institution in expanding the understanding of the causes, effects, and treatment of significant impairment of the human brain. Through the collaboration, BHRI will blend the practical application of medical therapies and treatment protocols with the advanced scientific analyses now available through personalized medicine and computational biology.
“This is a unique opportunity to bring the most advanced concepts in personalized medicine, with scientific rigor, to crippling diseases such as Alzheimer’s Disease,” said ISB President Dr. Jim Heath.
A bi-weekly science and medicine conference will be held at ISB and chaired by ISB Associate Director and Professor Dr. Nathan Price and BHRI’s Ross, and will track patient needs and explore ways ISB’s science can contribute to the battle against crippling neurodegenerative diseases.
Ross is joined by Drs. Kristine Lokken and Jeremy Whiting, and dementia coach Kerry Mills. The entire team recently moved to Seattle to open BHRI.
BHRI is located at 200 Mercer Street in Seattle (see map here). Patient-related questions should be directed to BHRI — please contact them here.